Latest news

FDA confirmed no additional studies required, existing longer-term data from the CAMPSIITE ® study will be reviewed on an expedited basis for approval via the accelerated approval pathway The Company expects to resubmit the BLA in Q3 2026 ROCKVILLE, Md., June 22, 2026 /PRNewswire/ -- REGENXBIO

ROCKVILLE, Md., May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2026 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 20 at 9:30am ET Location: New York, NY Stifel 2026 Virtual

Achieved primary endpoint with high statistical significance; 93% of patients achieved microdystrophin expression above 10% (p

Carolina Tesi-Rocha, M.D., Clinical Professor of Neuromuscular Medicine, Stanford Medicine Children’s Health

Charles C. Wykoff, M.D., PhD, Retina Consultants of Texas

REGENXBIO